ライフサイエンスコーパス: medullary thyroid cancer

1 tient (0.6%) died from incidentally detected medullary thyroid cancer.

2 MET in addition to VEGFR and is approved for medullary thyroid cancer.

3 ctivation of ATF4 during the pathogenesis of medullary thyroid cancer.

4 eted medical therapies are now available for medullary thyroid cancer.

5 n life for RET mutation carriers at risk for medullary thyroid cancer.

6 es has been advocated for early detection of medullary thyroid cancer.

7 on in a family with hereditary renal and non-medullary thyroid cancer.

8 dic counterpart, but is less aggressive than medullary thyroid cancer.

9 (ab)2 with AHSCR in patients with metastatic medullary thyroid cancer.

10 patients with rapidly progressing metastatic medullary thyroid cancer.

11 docrine neoplasia type 2 as well as sporadic medullary thyroid cancer.

12 asia type 2 (MEN2), which is associated with medullary thyroid cancer.

13 Medullary thyroid cancer (~4%) arises from parafollicula

14 family screening, these individuals' risk of medullary thyroid cancer and all-cause mortality without

15 ers without clinical disease before age 6 in medullary thyroid cancer and MEN type IIA, and as soon a

16 a role in Ras and Raf signal transduction in medullary thyroid cancer and other cells.

17 -degree relatives with histologically proven medullary thyroid cancer and phaeochromocytoma.

18 e contraindicated in those with a history of medullary thyroid cancer and used with caution in patien

19 s cabozantinib (FDA-approved for progressive medullary thyroid cancer) and PF-04217903 block their ac

20 nic RET variants, risk of clinically present medullary thyroid cancer, and all-cause mortality withou

21 RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely

22 Medullary thyroid cancer arises from calcitonin-producin

23 size to the uveal tract, even after decades; medullary thyroid cancer can be part of multiple endocri

24 their antiproliferative efficacy against the medullary thyroid cancer cell line TT.

25 es a program of differentiation in the human medullary thyroid cancer cell line TT.

26 Knockdown of RET by shRNA in medullary thyroid cancer-derived cells stimulated expres

27 At comparable masses, colorectal and medullary thyroid cancers had significantly higher tumor

28 nts that are approved for differentiated and medullary thyroid cancers have prolonged progression-fre

29 The prevention of medullary thyroid cancer in patients with multiple endoc

30 from a genome-wide association study of non-medullary thyroid cancer, including in total 3,001 patie

31 RET inhibition in medullary thyroid cancer is also being explored.

32 Familial medullary thyroid cancer may occur in isolation or as pa

33 Methods: Six patients with advanced medullary thyroid cancer (MTC) and 6 patients with other

34 Familial medullary thyroid cancer (MTC) and its precursor, C cell

35 Medullary thyroid cancer (MTC) can be caused by germline

36 Medullary thyroid cancer (MTC) cells characteristically

37 We have found, with human medullary thyroid cancer (MTC) cells, that activated Ras

38 ng chemicals targeting a Drosophila model of Medullary Thyroid Cancer (MTC) characterized by a transf

39 Standard treatment for patients with medullary thyroid cancer (MTC) consists of total thyroid

40 ity of nonendocrine manifestations preceding medullary thyroid cancer (MTC) for early diagnosis of mu

41 Patients with metastatic medullary thyroid cancer (MTC) have limited systemic tre

42 onstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.

43 tory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 years.

44 Medullary thyroid cancer (MTC) is an uncommon malignancy

45 Medullary thyroid cancer (MTC) is derived from the paraf

46 DNAs (cfDNAs) were analyzed in a RET-mutant medullary thyroid cancer (MTC) patient and a CCDC6-RET f

47 s institutional study aimed at quantifying a medullary thyroid cancer (MTC) patient's risk of lung, l

48 l blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC) patients.

49 oring the prospects of a cure for persistent medullary thyroid cancer (MTC) stratified by basal calci

50 e III trial involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy an

51 GS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokin

52 ll provide an update of important studies in medullary thyroid cancer (MTC) with an emphasis on targe

53 sess the targeting of established and occult medullary thyroid cancer (MTC) with radiolabeled monoclo

54 ranostics for the detection and treatment of medullary thyroid cancer (MTC), and the yet unresolved s

55 f cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an M

56 ttee on Cancer (AJCC) TNM staging system for medullary thyroid cancer (MTC).

57 tumors including small cell lung cancer and medullary thyroid cancer (MTC).

58 nresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

59 etastatic papillary thyroid cancer (PTC) and medullary thyroid cancer (MTC).

60 activity are critical in the pathogenesis of medullary thyroid cancer (MTC).

61 EN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC).

62 abeled NP-4 and MN-14 anti-CEA antibodies in medullary thyroid cancer (MTC).

63 rom LIBRETTO-001 in patients with RET-mutant medullary thyroid cancer (MTC; n = 324) and RET fusion-p

64 ged as a promising target for the therapy of medullary thyroid cancers (MTC) and of a subset of papil

65 an arise from parafollicular cells (familial medullary thyroid cancer) or from follicular cells (fami

66 lorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advan

67 ts (8 colorectal, 3 lung, 1 pancreatic and 1 medullary thyroid cancer) received RAIT with 131I-NP-4 F

68 ycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor

69 t breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications fo

70 The Kaplan-Meier estimated medullary thyroid cancer risk by age 75 years in variant

71 individuals from a US health system compared medullary thyroid cancer risk in these cohorts with 1078

72 s were associated with a substantially lower medullary thyroid cancer risk than clinically ascertaine

73 The discovery of a locally advanced medullary thyroid cancer that is not amenable to surgery

74 The hazard ratio for medullary thyroid cancer was 1.19 (0.37 to 3.86).

75 One of 5 medullary thyroid cancers was positive with the agonist,

76 CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastati

77 tients having minimal disease, as well as in medullary thyroid cancer, where cytotoxic tumor doses mi

78 In 88 patients with RET-mutant medullary thyroid cancer who had not previously received

79 secutively enrolled patients with RET-mutant medullary thyroid cancer who had previously received van

80 nly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vande

81 ment and treatment of patients with advanced medullary thyroid cancer with emphasis on current target

82 We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandet